Nature Communications2017ResearchNon-viral Gene Delivery

Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers

H.F. Moffett, M.E. Coon, S. Radtke, S.B. Stephan, L. Mcknight, A. Lambert, B.L. Stoddard, H.P. Kiem, M.T. Stephan29 September 2026DOI 10.1038/s41467-017-00505-8

Summary

Therapies based on genetically engineered immune cells (CAR T cells, HSCs) are transforming medicine, but the viral and electroporation methods used to create these cytoreagents are complex, expensive, and time-consuming. There is a growing need for transient "hit-and-run" genetic programming (transcription factors, genome-editing nucleases) where permanent transgene integration is undesirable or dangerous. A simple, non-viral method to. ### NP Characterization & Transfection Efficiency | Parameter | Result | |---------------|------------| | NP size | 109.6 ± 26.6 nm | | Zeta potential | 1.1 ± 5.3 mV (near-neutral) | | T cell transfection efficiency |.

Keywords

mRNANanocarriersCAR-T cellsT cellsTransfectionPoly(beta-amino ester)TCR signaling

Purpose: Therapies based on genetically engineered immune cells (CAR T cells, HSCs) are transforming medicine, but the viral and electroporation methods used to create these cytoreagents are complex, expensive, and time-consuming. There is a growing need for transient "hit-and-run" genetic programming (transcription factors, genome-editing nucleases) where permanent transgene integration is undesirable or dangerous. A simple, non-viral method to transiently program therapeutic cells without complex handling or reduced viability is needed.

Hypothesis: Targeted mRNA nanocarriers—simply mixed with cells in culture—can achieve efficient, dose-controlled transient gene expression in primary T lymphocytes and hematopoietic stem cells without compromising cell viability or function. This platform will enable: (1) efficient genome editing via megaTAL nuclease mRNA delivery; (2) reprogramming of CAR T cells toward a central memory phenotype via Foxo1 mRNA; and (3) improved self-renewal of HSCs via Musashi-2 mRNA, all without adding complexity to existing manufacturing protocols.

Aims: 1. Design and characterize targeted mRNA nanocarriers with four functional components: targeting antibodies, PGA shielding, PBAE carrier matrix, and modified mRNA payload 2. Demonstrate efficient transfection of primary T cells and HSCs with minimal impact on viability, proliferation, or function 3. Validate genome editing via delivery of mRNA encoding megaTAL nuclease to knockout TCR expression in CAR T cells 4. Reprogram T cell differentiation toward central memory phenotype via Foxo1 mRNA delivery and assess functional improvement in vivo 5. Enhance HSC self-renewal via Musashi-2 mRNA delivery and demonstrate improved clonogenic potential 6. Compare NP approach to electroporation in terms of simplicity, viability, and cell yield

Delivery system:

Component: Carrier Matrix; Description: PBAE 447 (poly(β-amino ester)) — biodegradable, half-life 1-7 h in aqueous conditions; condenses and protects mRNA

Component: Shielding Layer; Description: Polyglutamic acid (PGA, 15 kDa) — negatively charged, reduces off-target binding, neutralizes surface charge

Component: Targeting Ligands; Description: • T cells: anti-CD3 (OKT3), anti-CD8 (OKT8) • HSCs: anti-CD105 • Control: non-specific IgG

Component: Nucleic Acid; Description: Synthetic mRNA with modified nucleotides (pseudouridine + 5-methylcytidine) and ARCA cap; codon-optimized

Component: Transgenes Tested; Description: • eGFP (reporter) • TRAC-megaTAL nuclease + TREX2 (genome editing) • Foxo1₃A (AKT-insensitive, nuclear-retaining transcription factor) • Musashi-2 (MSI2; stem cell self-renewal factor)

Component: NP Properties; Description: • Size: 109.6 ± 26.6 nm • Zeta potential: 1.1 ± 5.3 mV (near-neutral) • Lyophilizable (stable with sucrose)

Component: Particle Formation; Description: Two-step self-assembly: (1) mRNA + PBAE (charge-driven condensation), (2) PGA-antibody addition

Component: Cell Types; Description: • Primary human T cells (PBMC-derived) • CD34⁺ HSCs (mobilized peripheral blood) • Jurkat T cell line

Approach:

Parameter: mRNA Transfection; Details: NP:T cell ratio = 2×10⁴:1; 2.5 µg mRNA/10⁶ cells; 2 h exposure at 37°C in XFSFM; cells diluted 4× with TCM + IL-2

Parameter: T Cell Stimulation; Details: CD3/CD28 Dynabeads (1:1 bead:cell ratio); beads removed 24 h before NP addition

Parameter: Genome Editing; Details: NP containing TRAC-megaTAL + TREX2 + eGFP mRNA (42:42:16 w:w:w); 30°C cold shock for 40 h post-transfection

Parameter: CAR T Cell Manufacturing; Details: Day 0: stimulation; Days 1-2: NP transfection; Day 3: lentiviral transduction (19-41BBζ CAR); expansion with TM-LCL feeders

Parameter: Foxo1 Reprogramming; Details: Foxo1₃A + eGFP mRNA (84:16 w:w); CD8-targeted NPs; transfection during primary and secondary expansion

Parameter: HSC Transfection; Details: CD34⁺ cells; 1 µg mRNA/well (96-well); 1 h exposure; CD105-targeted NPs

Parameter: In Vivo Model; Details: NSG mice; Raji-luc lymphoma (5×10⁵ cells i.v.); CAR T cells (2.5×10⁶ CD8⁺); IVIS bioluminescence imaging

Parameter: Controls; Details: eGFP mRNA NPs; non-targeting IgG NPs; untransfected cells; electroporation (Lonza Nucleofector)

Parameter: Replicates; Details: ≥3 independent experiments; n=9 mice/group for in vivo

Parameter: Statistical Tests; Details: Unpaired two-tailed Student's t-test; Log-rank test (survival); GSEA for RNAseq

Key methods:

Analysis Category: NP Characterization; Methods: DLS (size, zeta potential); TEM (morphology); lyophilization stability

Analysis Category: Transfection Efficiency; Methods: Flow cytometry (eGFP, cy5-labeled mRNA); confocal microscopy (internalization)

Analysis Category: Genome Editing; Methods: Surveyor assay (indel detection); flow cytometry (CD3 surface loss); TCRα PCR

Analysis Category: T Cell Phenotype; Methods: Flow cytometry: CD62L, CD45RO, CD28, S1PR1; RNASeq (Illumina HiSeq); GSEA

Analysis Category: T Cell Function; Methods: Proliferation (TM-LCL co-culture); Cytotoxicity (CD19+ K562, CFSE/7AAD); IFN-γ ELISA

Analysis Category: HSC Function; Methods: Flow cytometry: CD34, CD133, CD105; CFU assays (MethoCult H4435); qPCR (MSI2 mRNA)

Analysis Category: In Vivo Imaging; Methods: IVIS Spectrum; D-luciferin i.p.; Living Image software

Analysis Category: Gene Expression; Methods: qPCR (codon-optimized Foxo1₃A, MSI2); PrimeTime qPCR assays; QuantStudio5

Analysis Category: Cell Viability; Methods: 7AAD staining; trypan blue exclusion

Key results: ### NP Characterization & Transfection Efficiency

Parameter: NP size; Result: 109.6 ± 26.6 nm

Parameter: Zeta potential; Result: 1.1 ± 5.3 mV (near-neutral)

Parameter: T cell transfection efficiency; Result: >80% (single NP application)

Parameter: Transgene expression onset; Result: As early as 5 h post-transfection

Parameter: Lyophilization; Result: No change in properties or efficacy

Parameter: CD3-targeted NP selectivity; Result: Low off-target binding

T Cell Viability & Expansion vs. Electroporation:

Parameter: Handling complexity; mRNA NPs: Simple (mix with cells); Electroporation: Complex (multiple steps)

Parameter: Cell viability; mRNA NPs: Maintained; Electroporation: Compromised

Parameter: Cell yield; mRNA NPs: 60× higher than electroporation; Electroporation: Reduced

Parameter: Expansion with CD3/CD28 beads; mRNA NPs: Unimpaired even with repeated transfections; Electroporation: Not tested

TCR Knockout (Genome Editing):

Parameter: TCR knockout efficiency; Result: 60.8 ± 17.7% (day 14)

Parameter: Indel frequency; Result: Confirmed by Surveyor assay

Parameter: CAR transduction efficiency; Result: Equal in edited vs. control T cells

Parameter: T cell function post-editing; Result: Fully maintained (proliferation, killing, IFN-γ)

Foxo1₃A Reprogramming (T Cell Memory):

Parameter: Foxo1₃A mRNA expression; Result: Peak at day 1; near baseline by day 8

Parameter: Foxo1 protein levels; Result: Maintained near-physiological levels

Parameter: CD62L induction; Result: Rapid increase (within 24 h)

Parameter: CD62L persistence; Result: Maintained at days 8 and 20

Parameter: RNASeq; Result: Strong concordance with TCM gene signature

Parameter: Key memory genes upregulated; Result: KLF2, SELL, CD28, S1PR1

Parameter: Gene set enrichment; Result: Strong connection to TCM gene expression

In Vivo CAR T Cell Efficacy (NSG, Raji Lymphoma):

Parameter: Median survival; Control CAR T cells: 29 days; Foxo1₃A-NP CAR T cells: 43 days (14-day improvement)

Parameter: Tumor burden (day 14 post-therapy); Control CAR T cells: Baseline; Foxo1₃A-NP CAR T cells: 11.3× reduced vs. control CAR T cells

Parameter: Disease progression; Control CAR T cells: Temporary delay; Foxo1₃A-NP CAR T cells: Substantial regression

HSC Transfection & Expansion:

Parameter: HSC transfection efficiency (CD105-NPs); Result: 49.0 ± 6.9%

Parameter: HSC transfection (control IgG-NPs); Result: 4.9 ± 0.9%

Parameter: MSI2 mRNA expression; Result: Peak at day 1; near baseline by day 7

Parameter: CD34⁺CD133⁺ cells (day 8); Result: 2.6× increase (frequency)

Parameter: Total CD34⁺CD133⁺ cells; Result: 2.3× increase

Parameter: Differentiated CD34⁺ cells; Result: 2× reduction

Parameter: Colony forming units (CFC); Result: 30% overall increase

Parameter: BFU-E (erythroid); Result: 67% increase

Parameter: CFU-MIX (primitive); Result: 41% increase

Interpretation: The authors conclude that "exposing pharmaceutical cells to an NP reagent can improve their therapeutic value by accomplishing 'hit-and-run' gene modification." The platform "does not add complexity to manufacturing because it involves no special equipment or training," and "can substantially streamline the manufacture of cell-based therapies at clinical scales." Three examples—genome editing in CAR T cells (60.8% TCR knockout), memory phenotype reprogramming (14-day survival improvement in lymphoma model), and HSC expansion (30% increase in colony formation)—demonstrate that the approach is "simple and generalizable." The authors state: "Our project demonstrates that this platform can substantially streamline the manufacture of cell-based therapies at clinical scales, which means that treating patients with genetically engineered cells could become less expensive, and more effective as a disease-fighting intervention."

10. Limitations (Explicitly Stated or Evident):

1. Transient expression only: By design, the approach is "hit-and-run" and does not provide permanent transgene expression; this is an advantage for safety but limits applications requiring sustained expression.

2. In vitro HSC expansion not translated to in vivo engraftment: The study demonstrates improved HSC expansion and colony formation in vitro but does not show enhanced long-term engraftment or repopulation in vivo.

3. Cold shock required for genome editing: The authors used a transient cold shock (30°C for 40 h) to enhance genome editing, which adds complexity to the manufacturing process.

4. No direct comparison to viral transduction for permanent expression: The study compares NP transfection to electroporation but does not extensively benchmark against viral transduction for the same applications.

5. In vivo efficacy in NSG mice only: Immunodeficient NSG mice were used for in vivo CAR T cell studies; efficacy in immunocompetent models was not demonstrated.

6. PBAE polymer half-life: The PBAE formulation has a half-life of 1-7 h in aqueous conditions, requiring careful handling and potentially limiting in vivo stability.

7. Limited characterization of Foxo1 stability in vivo: While in vitro Foxo1 expression kinetics were measured, in vivo transgene expression kinetics after adoptive transfer were not tracked.

8. No evaluation of off-target effects: Genome editing specificity was not fully characterized; off-target nuclease activity was not systematically assessed.

9. CD105 targeting for HSCs: CD105 is expressed on primitive HSCs but also on other cell types; the specificity of targeting was not tested in a mixed cell population.

10. mRNA manufacturing complexity: While NP transfection is simple, manufacturing of modified mRNA at clinical scale remains complex and expensive.

11. No comparison to other non-viral delivery methods: The study compares NPs to electroporation but not to other emerging methods (e.g., lipid nanoparticles, cell-penetrating peptides).

12. Immunogenicity of modified mRNA: While modified nucleotides reduce immunogenicity, the authors did not assess whether repeated NP transfection elicits anti-mRNA or anti-NP immune responses.

Report prepared based on the published Nature Communications article. For full experimental details, supplementary figures, and complete references, please refer to the original publication.

Biomaterials Science

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programs with pharma, biotech and academic groups — from target selection through GMP supply.

Start a conversation Explore the pipeline

Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers

Summary

Keywords

Related articles

Approaches towards Biomaterial-Mediated Gene Editing for Cancer Immunotherapy

Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs

Cancer Immunotherapy and Nanomedicine

Let's engineer the next delivery breakthrough together